Skip to main content

Zofran ODT Disease Interactions

There are 2 disease interactions with Zofran ODT (ondansetron).


Ondansetron (applies to Zofran ODT) QT interval prolongation

Major Potential Hazard, Moderate plausibility. Applicable conditions: Hypokalemia, Magnesium Imbalance, Congestive Heart Failure, Arrhythmias

ECG changes including QT interval prolongation have been observed in patients receiving ondansetron. Additionally, there have been some postmarketing reports of Torsade de Pointes cases. The use of ondansetron should be avoided in patients with congenital long QT syndrome. ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.


  1. "Product Information. Zofran (ondansetron)." GlaxoSmithKline (2001):
  2. "Product Information. Zuplenz (ondansetron)." Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc. (2010):

Ondansetron (applies to Zofran ODT) liver disease

Moderate Potential Hazard, High plausibility.

Ondansetron is extensively metabolized by the liver. The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function. During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported. Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease. The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.


  1. Finn AL "Toxicity and side effects of ondansetron." Semin Oncol 19 (1992): 53-60
  2. Blake JC, Palmer JL, Minton NA, Burroughs AK "The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment." Br J Clin Pharmacol 35 (1993): 441-3
  3. Colthup PV, Palmer JL "The determination in plasma and pharmacokinetics of ondansetron." Eur J Cancer Clin Oncol 25 (1989): s71-4
  4. Bryson JC "Clinical safety of ondansetron." Semin Oncol 19 (1992): 26-32
  5. "Product Information. Zofran (ondansetron)." GlaxoSmithKline (2001):
  6. Verrill M, Judson I "Jaundice with ondansetron." Lancet 344 (1994): 190-1
  7. Roila F, Delfavero A "Ondansetron clinical pharmacokinetics." Clin Pharmacokinet 29 (1995): 95-109
  8. Figg WE, Dukes GE, Pritchard JF, et al. "Ondansetron (OND) pharmacokinetics in chronic liver disease (LD)." Clin Pharmacol Ther 51 (1992): 171
  9. Figg WD, Dukes GE, Pritchard JF, Hermann DJ, Lesesne HR, Carson SW, Songer SS, Powell R, Hak LJ "Pharmacokinetics of ondansetron in patients with hepatic insufficiency." J Clin Pharmacol 36 (1996): 206-15
View all 9 references

Zofran ODT drug interactions

There are 334 drug interactions with Zofran ODT (ondansetron).

Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.